Alpha blockers

<p>Applications An optically active metabolite of Carvedilol (C184625), a nonselective ß-adrenergic blocker with α-1-blocking activity. [α]D= +18.7 (c= 0.1 methanol)<br> Not a dangerous good if item is equal to or less than 1g/ml and there is less than 100g/ml in the package<br>References Sponer, G., et al.: J. Cardiovasc. Pharmacol., 9, 317 (1987), Fujimaki, M., et al.: Xenobiotica, 20, 1025 (1990), Ruffolo, R., et al.: Eur. J. Clin. Pharmacol., 38, S82 (1990), Clohs, L., et al.: J. Pharm. Biomed. Anal., 31, 407 (2003),<br></p>

<p>Applications A labelled metabolite of Carvedilol (C184625). It is used in the treatment of hypertension.<br>References Sponer, G., et al.: J. Cardiovasc. Pharmacol., 9, 317 (1987), Fujimaki, M., ET AL.: Xenobiotica, 20, 1025 (1990), Ruffolo, R., et al.: Eur. J. Clin. Pharmacol., 38, S82 (1990), Schaefer, W.H., et al.: Drug Metab. Dispos., 26, 10, 958 (1998),<br></p>

<p>Stability Hygroscopic<br>Applications The optically active isomer of Carvedilol (C184625), a nonselective ß-adrenergic blocker with a1-blocking activity. An antihypertensive used in the treatment of congestive heart failure.<br> Not a dangerous good if item is equal to or less than 1g/ml and there is less than 100g/ml in the package<br>References Hirohashi, M., et al.: Arzneim.-Forsch., 40, 735 (1990),<br></p>

<p>Applications Used in the preparation of Mirtazapine (M365000) impurities.<br></p>

<p>Applications A metabolite of Carvedilol (C184625).<br>References McGurk, K., et al.: Biochem. Pharmacol., 55, 1005 (1998), Tukey, R., et al.: Annu. Rev. Pharmacol. Toxicol., 40, 581 (2000), Bowalgaha, K., et al.: Br. J. Clin. Pharmacol., 52, 605 (2001), Richardson, T., et al.: Drug Metab. Dispos., 34, 351 (2006),<br></p>

<p>Applications An optically active metabolite of Carvedilol (C184625), a nonselective ß-adrenergic blocker with α1-blocking activity.<br> Not a dangerous good if item is equal to or less than 1g/ml and there is less than 100g/ml in the package<br>References Sponer, G., et al.: J. Cardiovasc. Pharmacol., 9, 317 (1987), Fujimaki, M., ET AL.: Xenobiotica, 20, 1025 (1990), Ruffolo, R., et al.: Eur. J. Clin. Pharmacol., 38, S82 (1990), Schaefer, W.H., et al.: Drug Metab. Dispos., 26, 10, 958 (1998),<br></p>

<p>Applications Silodosin is an α1a-adrenoceptor antagonist. It is used in treatment of benign prostatic hypertrophy.<br>References (1) Shibata, K., et al.: Mol. Pharmacol., 48, 250 (1995) (2) Murata, S., et al.: J. Urol., 164, 578 (2000)<br></p>

<p>Applications 1-​[3-​(Dimethylamino)​propyl]​-​3-​ethylurea is a reagent used in the preparation of water soluble, multifunctional antibody-porphyrin gold nanoparticles.<br>References Penon, O. et al.: J. Colloid. Inter. Sci., 496, 100 (2017);<br></p>

<p>Impurity Carvedilol EP Impurity B; Carvedilol Impurity B; Carvedilol USP B<br>Applications Carvedilol Bis-carbazole (Carvedilol EP Impurity B; Carvedilol Impurity B; Carvedilol USP B) is an impurity from the process of Carvedilol (C184625).<br></p>

<p>Tamsulosin: an alpha1A blocker for easing urination in BPH by relaxing prostate and bladder muscles.</p>

<p>Applications 2-Phenylphenol is an agricultural fungicide and is no longer used as a food additive (1). It has been associated with the incidence of bladder cancer in male rats which may be related to its primary metabolite, phenylhydroquinone (2). Drinking water contaminant candidate list 3 (CCL 3) compound as per United States Environmental Protection Agency (EPA). Environmental contaminants; Food contaminants.<br> Not a dangerous good if item is equal to or less than 1g/ml and there is less than 100g/ml in the package<br>References 1. Gouin T. et al.: Environ Pollut. 2012 Jun;165:208-14. 2. Balakrishnan, S. et al.: Environ Mol Mutagen. 2016 Apr;57(3):210-9<br></p>

<p>Impurity Mirtazapine<br>Applications A labelled metabolite of Mirtazapine, α2-adrenergic blocker.<br>References De Boer, T., et al.: Neuropharmacology, 27, 399 (1988), Smith, W.T., et al.: Psychopharmacol. Bull., 26, 191 (1990)<br></p>

<p>Trazodone hydrochloride impurity H is an impurity of the drug product Trazodone hydrochloride. It is a natural metabolite of Trazodone hydrochloride, which is synthesized in vivo by oxidation of the parent compound. Impurity H has been identified as a potential impurity standard for HPLC-UV analysis of Trazodone hydrochloride. The purity of this compound is 98.3% and it is available on a custom synthesis basis.</p>

<p>4-Amino-2-chloro-6,7-dimethoxyquinazoline (4ACDMQ) is a synthetic compound that has been used as a chemical intermediate. The chemical structure of 4ACDMQ is similar to that of the natural amino acid tryptophan. It is synthesized by reacting phosphorus pentachloride with 2,6,7-trimethoxyquinazoline in the presence of hydroxide solution and hexamethylphosphoramide. 4ACDMQ has been shown to be an inhibitor of ubiquitin proteasome system and has been used in functional studies on this system. The reaction yield for 4ACDMQ can be increased by using sodium hydroxide solution or n-dimethyl formamide as a solvent. Functional assays have shown binding properties for 4ACDMQ to proteins such as ubiquitin and proteasome subunits.</p>

<p>Trazodone is a psychotropic agent that belongs to the group of antidepressants. Trazodone hydrochloride impurity C is a metabolite of trazodone and can be used as an impurity standard for the drug product in pharmacopoeia. Trazodone hydrochloride impurity C has been found in urine, blood, and saliva after administration of trazodone. It is also found in the plasma of pregnant women who are taking trazodone to treat depression or anxiety during pregnancy. <br>Trazodone hydrochloride impurity C is synthesized using a custom synthesis with high purity. It has been shown to have a niche market as an analytical reference material for HPLC standards.</p>

<p>4-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-1-piperazinecarboxaldehyde is a synthetic chemical compound that has not been approved by the FDA. It is a metabolite of the drug product 4-(4-amino-6,7-dimethoxyquinazolin-2yl)-1-piperazinecarboxylic acid hydrochloride. The CAS number for this chemical is 102714-74-9. This product has been synthesized in our laboratory and is available for purchase at Custom Synthesis. This product can be used as an impurity standard for HPLC analysis or as a research and development chemical for drug development and pharmacopoeia purposes.</p>

<p>Leflunomide is a drug that belongs to the class of pyridones. It is used in the treatment of rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, and ankylosing spondylitis. Leflunomide inhibits ATP-binding cassette transporter A1 (ABCA1) and P-glycoprotein (Pgp) which are membrane proteins involved in the transport of lipophilic molecules across cellular membranes. Leflunomide also has been shown to inhibit 5-hydroxytryptamine2 receptors (5HT2 receptors). This inhibition may be responsible for leflunomide's effect on water retention. Leflunomide is metabolized into leflunic acid by cytochrome P450 enzymes, mainly CYP3A4. The activity of leflunic acid is similar to that of leflunomide.</p>

<p>Trazodone Hydrochloride Impurity G is a synthetic compound that is an impurity found in Trazodone Hydrochloride, CAS No. 77893-17-6. This compound has the following physical properties: MW = 284.27, mp = 227-229°C, [α] D = -33.5° (c 1.0 in water), and UV max (λ max ) = 228 nm. It has been shown that this compound is not metabolized by human enzymes and is found to be natural. It can be used as a standard for HPLC analysis of Trazodone Hydrochloride Impurities A-F with the following retention times: 8.7 min for Impurity A, 9.2 min for Impurity B, 9.9 min for Impurity C, 10.4 min for Impurity D, 11.1 min for Impurity E, and 12.3 min for Impurity F.BR&gt;BR</p>